Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to assess immunogenicity and safety of GSK Biologicals\' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.
Epistemonikos ID: ce184d5f379e0b76c4ea5498ae90e92bfb1c2f64
First added on: May 21, 2024